MedTrace Logo

A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer

NCT00796107 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2020-11-13

Study results available
· View outcomes & findings →

Summary

This study aim was to determine the safety and efficacy of R1507 in combination with letrozole in patients with advanced breast cancer. In the first part of the study a cohort of patients with advanced breast cancer received letrozole 2.5mg po daily in combination with R1507 16mg/kg every 3 weeks.

Conditions

Interventions

DRUG

RG1507

R1507 was administered at a dose 16 mg/kg every 3 weeks.

DRUG

Letrozole

Letrozole was administered orally at a dose 2.5 mg daily.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-28
Primary Completion
2010-03-03
Completion
2010-03-03

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00796107 on ClinicalTrials.gov